|
Session 128
Poster Abstracts
Renal Dysfunction: Role of HIV and ART
Wednesday, 1-2:30 pm
Poster Hall |
740
 |
Markers of Inflammation, Coagulation, and Renal Function in HIV-infected Adults in the Strategies for Management of ART Study and in 2 Large Population-based Studies, Coronary Artery Risk Development in Young Adults and Multi-Ethnic Study of Atherosclerosis
Jacqueline Neuhaus*, D Jacobs, and the INSIGHT SMART, MESA and CARDIA Study Groups
Univ of Minnesota, Minneapolis, US |
741
|
The Relationships between Renal Dysfunction and Clinical Outcomes in HIViInfected Kenyans Not Requiring Immediate ART
Kara Wools-Kaloustian*1, W Owino On G’or2,3, S Wafula3, C Shen1, B Musick1, M Goldman1, and S Gupta1
1Indiana Univ Sch of Med, Indianapolis, US; 2Moi Univ Sch of Med, Eldoret, Kenya; and 3US Agency for Intl Devt, Academic Model for the Prevention and Treatment of HIV/AIDS |
| 742 |
Greater Renal Function Preservation Is Associated with Continuous vs Intermittent ART
D Beversluis1, S Reynolds2, C Kityo3, R Salata1, M Dybul4, P Mugyenyi3, R Davey5, D AtwIIne3, T Quinn2, and Robert Kalayjian*1
1Case Western Reserve Univ Sch of Med, Cleveland, OH, US; 2Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 3Joint Clinical Res Ctr, Kampala, Uganda; 4UNAIDS, Geneva, Switzerland; and 5NIAID, NIH, Bethesda, MD, US |
743
|
Tenofovir and PI Use Are Associated with an Increased Prevalence of Proximal Renal Tubular Dysfunction in the Swiss HIV Cohort Study
Christoph Fux*1, M Opravil2, M Cavassini3, A Calmy4, M Flepp5, V Gurtner-Delafuente6, M Stoeckle7, P Schmid8, A Rauch1, H Furrer1, and Swiss HIV Cohort Study (SHCS)
1Univ Hosp Bern, Switzerland; 2Univ Hosp Zurich, Switzerland; 3Ctr Hosp Univ Vaudois, Lausanna, Switzerland; 4Univ Hosp Geneva, Switzerland; 5Klinik im Park, Zurich, Switzerland; 6Civic Hosp, Lugano, Switzerland; 7Univ Hosp Basel, Switzerland; and 8Cantonal Hosp, St Gallen, Switzerland |
744
|
Assessment of Renal Findings of Abacavir/Lamivudine Compared with Tenofovir/Emtricitabine in Combination with Once-daily Lopinavir/Ritonavir over 96 Weeks in the HEAT Study
Derek Fine*1, K Smith2, P Patel3, N Bellos4, L Sloan5, P Lackey6, P Kumar7, D Sutherland-Phillips3, L Yau3, and M Shaefer3
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2Rush Univ Med Ctr, Chicago, IL, US; 3GlaxoSmithKline, Research Triangle Park, NC, US; 4Southwest Infectious Disease Assoc, Dallas, TX, US; 5North Texas Infectious Disease Consultants, Dallas, US; 6ID Consultants, Charlotte, NC, US; and 7Georgetown Univ Sch of Med, Washington, DC, US |
| 745 |
Impairment in Kidney Tubular Function in Patients Receiving Tenofovir Is Associated with Higher Plasma Tenofovir Levels
Sonia Rodriguez Novoa*1, P Labarga1, A D´avolio2, P Barreiro1, M Albalater3, C Solera1, M Siccardi2, S Bonora2, G Di Perri2, and V Soriano1
1Hosp Carlos III, Madrid, Spain; 2Univ of Torino, Italy; and 3Fndn Jimenez-Diaz, Madrid, Spain |
746
|
Associations between Endothelial Dysfunction and Proteinuria, Albuminuria, and Renal Function in Stable, HIV-infected Patients
Samir Gupta*1, C Shen1, C Saha1, K Mather1, J Waltz1, M Greenwald1, and M Dubé2
1Indiana Univ Sch of Med, Indianapolis, US and 2Univ of Southern California, Keck Sch of Med, Los Angeles, US |
|
